• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Neuropsychological changes following deep brain stimulation surgery for Parkinson's disease: comparisons of treatment at pallidal and subthalamic targets versus best medical therapy
Conclusions In those with PD, the likelihood of significant decline in neuropsychological functioning increases with DBS, affecting a small minority of patients who also appear to respond less optimally to DBS by other indicators of QOL. Trial registration number NCT00056563 and NCT01076452.
Source: Journal of Neurology, Neurosurgery and Psychiatry - May 14, 2015 Category: Neurosurgery Authors: Rothlind, J. C., York, M. K., Carlson, K., Luo, P., Marks, W. J., Weaver, F. M., Stern, M., Follett, K., Reda, D., Ippolito, Stoner, Barnett, Bukowski, DeNicolo, Hur, Jimenez, Motyka, Simon, Thakkar, Woolson, Fye, Gagne, Harris, Heemskerk, Moy, Sheehy, O' Tags: Drugs: CNS (not psychiatric), Parkinson's disease, Stroke, Memory disorders (psychiatry) Multiple sclerosis Source Type: research

The Dance Between The Immune System and Stem Cells
We named it the  immunoLinkTM We have been testing a growing number of Clients with our Quantibody Arrays. Many of of these clients have Autoimmune Disorder Diseases. These range from Rheumatoid Arthritis to Multiple Sclerosis.These arrays are designed to precisely measure factors or markers (proteins) that are dysregulated by these diseases. We measure the levels of these biomarkers in our Clients' Blood serum. The arrays have also been used to measure the levels of markers in plasma and cell culture supernatants.Based on results, we are finding links between immune system and stem cell health. We call this the ...
Source: Neuromics - September 30, 2014 Category: Neuroscience Tags: autoimmune disease G-CSF GM-CSF Human Mesenchymal Stem Cells immune response immunoLink Neural Progenitor Cells Neural Stem Cell Markers Source Type: news

Chronic over‐expression of TGFβ1 alters hippocampal structure and causes learning deficits
Abstract The cytokine Transforming Growth Factor β1 (TGFβ1) is chronically upregulated in several neurodegenerative conditions, including Alzheimer's disease, Parkinson's disease, Creutzfeldt‐Jacob disease, amyotrophic lateral sclerosis and multiple sclerosis, and following stroke. While previous studies have shown that TGFβ1 may be neuroprotective, chronic exposure to elevated levels of this cytokine may contribute to disease pathology on its own. In order to study the effects of chronic exposure to TGFβ1 in isolation we used transgenic mice that over‐express a constitutively active porcine TGFβ1 in astrocytes. W...
Source: Hippocampus - June 27, 2013 Category: Neurology Authors: Alonso Martinez‐Canabal, Anne L. Wheeler, Dani Sarkis, Jason P. Lerch, Wei‐Yang Lu, Marion S. Buckwalter, Tony Wyss‐Coray, Sheena A. Josselyn, Paul W. Frankland Tags: Research Article Source Type: research

157 E-Books New to JEFFLINE
Scott Library added these 157 e-books to the growing collection in May and June: Accurate Results in the Clinical Laboratory Adult Emergency Medicine Adult-Gerontology and Family Nurse Practitioner Certification Examination (4th ed.) Advanced Assessment: Interpreting Findings and Formulating Differential Diagnoses (2nd ed.) Advancing Your Career: Concepts of Professional Nursing (5th ed.) Arrhythmia Essentials Atlas of Advanced Operative Surgery Atlas of Clinical Neurology (3rd ed.) Atlas of Hematopathology: Morphology, Immunophenotype, Cytogenetics, and Molecular Approaches Atlas of Human Infectious Diseases Atlas of No...
Source: What's New on JEFFLINE - June 25, 2013 Category: Databases & Libraries Authors: Gary Kaplan Tags: All News Clinicians Researchers Students Teaching Faculty Source Type: news

Derivatives of Docosahexaenoylethanolamide (DEA) for Neurogenesis
The invention pertains to derivatives of docosahexaenoylethanolamide (synaptamide or DEA) and their use in inducing neurogenesis, neurite growth, and/or synaptogenesis. As such, these DEA derivatives can be used as therapeutics for neurodegenerative diseases such as traumatic brain injury, spinal cord injury, peripheral nerve injury, stroke, multiple sclerosis, autism, Alzheimer ' s disease, Huntington ' s disease, Parkinson ' s disease, amyotrophic lateral sclerosis. The DEA derivatives of the invention have increased potency and hydrolysis resistance as compared to native DEA. Docosahexaenoic acid (DHA), an n-3 polyunsat...
Source: NIH OTT Licensing Opportunities - January 24, 2013 Category: Research Authors: ajoyprabhu3 Source Type: research

Novel Derivatives of Docosahexaenoylethanolamide as Therapeutics for Neuronal Disorders
This technology provides derivatives of Docosahexaenoylethanolamide (synaptamide or DEA) which have increased potency and hydrolysis resistance as compared to DEA (structures of these derivatives are available upon request), as well as methods of using these derivatives to promote neurogenesis, neurite growth, and/or synaptogenesis. Docosahexaenoic acid (DHA), an n-3 polyunsaturated fatty acid that accumulates in the brain during development, has been shown to play a key role in learning and memory development. Studies have also shown that DEA, a metabolite derived from DHA is very potent in accelerating neuronal growth an...
Source: NIH OTT Licensing Opportunities - January 24, 2013 Category: Research Authors: admin Source Type: research

Pages: 1  2  3  4